A novel tablet formulation of ketamine has demonstrated potential in the treatment of severe depression, providing a possible substitute for the...

OSAKA, Japan and CAMBRIDGE, Massachusetts, June 22, 2024 – Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b,...

Prolonged-release ketamine tablet has potential as affordable and convenient treatment for severe depression and with minimal side effects

TUESDAY, June 25, 2024 -- A new slow-release pill form of ketamine can quell hard-to-treat depression without producing psychedelic side effects...

71% of patients found to experience a relapse compared with 43% who received the pills twice a week

Results from a new trial indicate that immunotherapy could successfully be used to treat the most common form of colorectal cancer, also known as...

WA’s first trial of psilocybin - from magic mushrooms - to help treatment-resistant depression is underway, with the first patient reporting good...

Results of a phase 3 PURPOSE 1 HIV prevention study done among adolescent girls and young women in South Africa and Uganda show that there were no...

Biotron (ASX:BIT) jumped +15% this morning after announcing promising results from its BIT225-011 Phase 2 clinical trial. ...